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Abstract 
 
Cyanobactins are a diverse collection of natural products that originate from 
short peptides made on a ribosome. The amino acids are modified in a series 
of transformations catalyzed by multiple enzymes. The patellamide pathway is 
the most well studied and characterized example. Here we review the 
structures and mechanisms of the enzymes that cleave peptide bonds, 
macrocyclise peptides, heterocyclise cysteine (as well as threonine and 
serine) residues, oxidize five-membered heterocycles and attach prenyl 
groups. Some enzymes operate by novel mechanisms which is of interest and 
in addition the enzymes uncouple recognition from catalysis. The normally 
tight relationship between these factors hinders biotechnology. The 
cyanobactin pathway may be particularly suitable for exploitation with 
progress in vivo and in vitro approaches observed.  
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Introduction 
Despite approximately 3000 human genes having been estimated to be 
involved in disease states, only a fraction (between 20 and 50 %) are thought 
to be potentially responsive to inhibition by traditional small molecule drugs 
[1]. Natural products (NPs) have long been successfully employed to bridge 
the gap between inhibitors and “undrugable” targets [2]. A particularly 
promising class of NPs is the ribosomally synthesized and post-translationally 
modified peptides (RiPPs). These NPs offer the practicality of genetically 
encoded compound libraries, which can be readily derivatized both 
enzymatically and chemically giving rise to very diverse molecules. 
 
Cyanobactins are RiPPs which in general, although not always, contain a 
macrocyclic ring – forming a peptide bond between the N-terminal amine and 
another amino acid next to a recognition sequence. They can also contain 
heterocyclized (cyclodehydratized) serine, threonine and/or cysteine residues 
yielding (methyl)oxazoline and thiazoline rings or isoprenoid amino acids 
derivatives [3,4]. Cyanobactins are encoded as a precursor peptide (“E” on 
figure 1A) which possesses a leader sequence recognized by the 
cyclodehydratase proteins responsible for heterocycle formation (“D” on figure 
1A). Once heterocyclized, the precursor peptide is cleaved by a serine 
protease (“A” on figure 1A) to contain solely the core natural product 
sequence followed by a short recognition sequence. The core peptide 
sequence is then macrocyclized by another serine protease working “in 
reverse”, i.e. catalysing peptide bond formation to yield the cyclic peptide (“G” 
on figure 1A). The cyclic peptide can then be further post-translationally 
modified by prenylation (“F” on figure 1A) and/or oxidation to include thiazoles 
and oxazoles (Oxidase domain of the “G” protein on figure 1A). 
This pathway, albeit extremely promising in terms of generating RiPPs 
diversity, has several defects from a technology view that should be improved 
to make the production of diverse cyclic peptides in large scale routine. 
Several approaches have been used to trim the precursor peptide by 
eliminating the requirement of a long peptide leader (which is discarded 
during processing) [5**], to introduce unnatural amino acids, to process long 
sequences in the core peptide [6*,7**], to devise chimeric pathways utilizing 
enzymes from different pathways and organisms and to produce cyanobactins 
in vitro in a one-pot reaction [7**,8]. Figure 1B schematically illustrates the 
progress made so far and highlights targets for further improvement. Our 
understanding of the catalytic and chemical mechanisms of the enzymes 
involved in cyanobactin biosynthesis has greatly increased in the past few 
years. In this review article we discuss the major discoveries and current 
proposed mechanisms for the enzymes involved in cyanobactin biosynthesis. 
 
Figure 1 HERE 
 
Heterocyclase 
Peptide heterocycles reduce polarity, add chemical diversity and 
conformational rigidity to peptides. They are common in both linear and 
macrocyclic bioactive natural products [9,10]. Many cyanobactins, such as 
patellamides [11-15], trunkamides [16,17] and microcyclamides [18-20] 
contain thiazol(in)e or oxazol(in)e rings within their cyclic backbones. 
Phylogenetic studies [21-23] showed that clusters capable of biosynthesizing 
cyanobactins that bear heterocycles encode a YcaO domain-containing 
heterocyclase (cyclodehydratase), denoted in each pathway the letter D 
preceded by the name of that pathway, such as PatD (“D” on figure 1A). An 
optional, FMN-dependent oxidase (dehydrogenase) – discussed below – may 
also be present, either as a domain of the protein G or as a separate gene 
product, and carry out the dehydrogenation of thiazoline and oxazoline 
moieties to thiazoles and oxazoles, respectively [23,24]. PatD-like 
heterocyclases were shown to use a range of natural and unnatural 
substrates, including those containing non-proteinogenic amino acids and 
non-amino acids [5**,6*,7**,21,25-29*]. The promiscuity of this class of 
enzymes make them desirable tools for the creation of libraries of 
heterocycle-containing compounds, either as part of a system leading to 
cyanobactin-like macrocycles [29*] or as stand-alone enzymes. 
 
Heterocyclization by PatD-like heterocyclases is both ATP and magnesium 
dependent, as are other YcaO domain-containing enzymes such as the  
thiazole/oxazole-modified microcin (TOMM) heterocyclase BalhD from 
Bacillus sp. Al Hakam [30-32]. Heterocycles on RiPPs form through the 
reaction between the hydroxyl or sulfhydryl group from serine, threonine or 
cysteine residues and the amide bond N-terminal to it [4]. An electron pair 
from the heteroatom on the amino acid side chain attacks the carbonyl 
oxygen of the amide bond, leading to the formation of a hemiorthoamide 
(Figure 2F), which subsequently attacks ATP on one of the phosphate atoms, 
forming an adenylate, and a phosphoryl or pyrophosphoryl leaving group [33]. 
An unambiguous mechanism for the nucleophilic attack by the tetrahedral 
oxygen has yet to be established. ADP and inorganic phosphate (Pi) were 
observed as the product of ATP hydrolysis during microcin B17 biosynthesis 
and the BalhC/D systems, establishing a kinase mechanism (Figure 2F) 
[4,33]. Structural analyses of ATP-bound E. coli YcaO and LynD supported 
this showing the γ-phosphate exposed to attack and the α-phosphate 
shielded by the protein [5**,33]. However, AMP and pyrophosphate (PPi) 
have been detected during catalysis by TruD and LynD [5**,27]. Furthermore, 
E. coli YcaO, whose function is unknown, hydrolyzed ATP to AMP and PPi 
[34]. 
 
Substrate recognition by PatD-class of enzymes combines almost complete 
insensitivity to the residues flanking the transformed residue within core 
region with binding to a sequence in the N-terminal leader [5**,26,27]. The 
use of a leader sequence is also seen in the biosynthetic transformation of 
other RiPPs [3,35]. Despite the lack of sequence similarities between the 
leader peptides of different classes of RiPPs, their recognition proteins share 
a structural motif for peptide interaction, identified and named ‘RiPP precursor 
peptide recognition element (RRE)’ by a recent bioinformatics study [36**]. 
For instance, LynD (Figure 2A) and the lantibiotic nisin dehydratase NisB 
recognize the consensus sequences ‘LAELSEEAL’ and ‘FNDL’, respectively 
[5**,37]. However, both utilized a ‘peptide clump’ (Figure 2C) consisting of 
three alpha helices and three beta sheets (winged helix-turn helix motif) on 
the enzyme [5**,36**,37]. These interactions position the core region, which is 
C-terminal to the leader such that it reaches the active site of the enzyme for 
post-translational modification to take place [5**,37]. 
 
FIGURE 2 HERE 
 
The leader peptide activates the cyanobactin heterocyclase whether added in 
trans or in cis [26]. The structure of PatE’-bound to LynD, revealed the peptide 
recognition residues interact simultaneously with the N-terminal domain of 
one enzyme monomer and the C-terminal catalytic domain of the other 
enzyme monomer in the enzyme dimer. The second interaction orders an 
active site loop proving a rationale for enzyme activation (Figure 2B) [5**]. The 
presence of the recognition sequence is essential for the processivity of the 
enzyme [5**,26,27]. Cognate leader peptides added in trans, have also been 
shown to enhance the activities of the lacticin 481 synthetase LctM, and the 
nisin synthetases NisB and NisC [38,39]. Both LctM and LynD have been 
engineered to include their cognate leader (or part) peptide and display 
increased activity [5**,40]. The engineered LynD (LynD fusion) is capable of 
processively processing peptides that have no sequence N-terminal to the 
core (Figure 2E) [5**]. This fusion protein is a useful tool in biotechnology as it 
allows the facile use of entirely synthetic substrates. 
 
Protease 
The crystal structures of proteases PatA and PagA	 [41,42] reveal the same 
catalytic triad – composed of serine, aspartate and histidine and typical of 
subtilisin-like serine proteases	 [43], the macrocyclase domain of PatG shares 
this fold (Figure 3a). The similarity was predicted on sequence grounds and 
mechanistically is unsurprising since both the protease and macrocyclase 
form an acyl enzyme intermediate; the difference is the fate of this 
intermediate. The current proposed catalytic mechanism for both A and G 
proteins is shown in Figure 3b. A similar trend in which very subtle differences 
in primary sequence set apart peptide bond formation and cleavage has been 
observed in evolutionarily distant macrocyclases from Amanita and Galerina  
mushrooms [44,45]. 
Unfortunately, the crystal structure for PatGmac lacks electron density for the 
N-terminal amine of the core peptide sequence [42], which precludes any 
conclusions as to how substrate positioning is affecting catalysis. The 
hypothesis that positioning plays only a minor role in the reaction catalyzed by 
the macrocyclase enzyme is substantiated by empirical evidence as to the 
notable substrate promiscuity it possesses. Peptides with remarkable 
variability, containing from 6 to 22 amino acids in the core region and a 
combination of natural and unnatural amino acids have been successfully 
macrocyclized, as long as they possess the signature sequence 
proline/heterocycle)-AYD [29*]. Recently, peptide substrates containing up to 
three triazole groups were shown to be macrocyclized [46**], further 
expanding the substrate scope of the macrocyclase enzyme to include non-
peptidic scaffolds. 
 
FIGURE 3 HERE 
 
Sortase A, another enzyme frequently used for peptide or protein ligation, 
requires the sequence LPXTG for substrate recognition, as well as at least 
one glycine in the nucleophilic sequence [47]. Despite the fact that a sortase 
with broader substrate specificity has been identified by directed evolution 
[48], because the sequence LPXTG (or similar) is retained after cyclization, 
sortase reactions efficiently produce peptides with fifteen amino acids or more 
[49].  
The hydrolysis reaction catalyzed by PatA is several orders of magnitude 
slower than observed for other proteases [50] and turnover numbers in the 
vicinity of 1 day-1 for the macrocyclase enzyme have been reported 
[42,50,51]. The in vitro synthesis of patellamides requires a “lag” between the 
production of the precursor peptide “E” and cleavage of the leader, since the 
heterocyclase enzyme needs to convert serines/threonines/cysteines to their 
respective heterocyclic products prior to leader removal. The reason 
underlying PatGmac’s poor catalytic efficiency could lie on the fact that the 
macrocyclase enzyme seems to trade-off efficiency for a very simple 
recognition motif. Much faster macrocyclase enzymes Butelase 1, PCY1, 
(both from plant) and POPB, from mushroom [44,52,53*,54] have been 
reported but they require more than the simple heterocycle plus three residue 
motif of PatGmac. Alternatively the macrocyclase enzyme may have evolved 
to be bottleneck of the process regulating production of biologically active 
products [7**,41]. 
 
Oxidase 
Following heterocyclization, thiazolines and oxazolines are in many cases 
oxidised by a flavin mononucleotide (FMN)-dependent dehydrogenase to yield 
thiazoles and oxazoles [4]. In the biosynthesis of microcin, a linear RiPP, the 
same order was observed for heterocyclization and oxidation starting on the 
C-terminus and proceeding towards the N-terminus of the peptide substrate. 
Oxidase enzymes from related organisms were successfully employed 
interchangeably but more distantly related (in sequence terms) enzymes 
failed to produce azole products [32,33,55,56**]. 
Despite substantial information available on the substrate preference in terms 
of specificity/promiscuity of enzymes catalyzing oxazoline/thiazoline oxidation, 
as well as order of reaction [8,56**,57], little information is available about the 
catalytic and chemical mechanism by which these reactions proceed. Primary 
sequence alignments with FMN-bound dehydrogenases from RiPPs and non-
ribosomal peptide (NRPs) synthetases show little sequence homology. The 
only highly conserved residues apart from those known to be involved in FMN 
binding are a lysine-tyrosine motif (KY-motif) [56**]. Mutagenesis of the KY 
motif stops the production of microcin B17 in vitro, as well as the oxidation of 
a BalhA substrate [58]. BcerB from Bacillus cereus 172560W showed reduced 
activity when K185A mutant was tested, whereas both Y186A and the double 
mutant K185A/Y186A were inactive	 [56**]. Analogously, in the related enzyme 
from Sulfolobus acidocaldarius  DSM 639, SaciB, mutation of either lysine or 
tyrosine resulted in complete loss of activity	 [56**]. A mechanism for oxidation 
has been proposed based on for EpoB and BlmIII, NRPs enzymes catalyzing 
thiazole formation in epothilone and bleomycin biosynthesis (Figure 4a) [59]. 
 
FIGURE 4 HERE 
 
Prenylase 
O-prenylation of serine, threonine and tyrosine residues are found in 
prenylagaramides, aestuaramides and trunkamides [3,21,60-64] and is 
catalyzed by a prenylase enzyme, exemplified by LynF [65]. The 
dimethylallylpyrophosphate (DMAPP) group on tyrosine has been shown to 
undergo non-enzymatic Claisen rearrangement to give C-prenylated products 
(Figure 4b) [62,65,66]. Although LynF-like enzyme only exhibited activity on 
cyclic substrates, distantly related small, linear cyanobactins such as 
viridisamides undergo prenylation on the N-terminus [22], indicating another 
mode of prenylation in the cyanobactin family. Moreover, C-3-prenylation of 
tryptophan residues was observed in Kawaguchipeptins from Mycrocystis 
aeruginosa NIES-88 [67*]. In vitro expression of the biosynthetic operon 
showed that both linear and cyclic substrates are accepted by the putative 
prenyltransferase, KgpF, (related in sequence to other cyanobactin 
prenylases [67*]). Interestingly the patellamide pathway has a prenylase, PatF 
whose structure is known [68], but the pathway does not make prenylated 
products and the enzyme is inactive [68]. 
 
Future Directions 
Figure 1b highlights the progress made so far towards understanding 
biosynthetic enzymes and substrates involved in cyanobactins and RiPPs. 
Significant improvements in in vivo production of patellin, trunkamide and 
patellamide C have been reported allowing large sale efficient production of 
desired material [69**]. The production of highly diverse peptide libraries for 
high throughput screening would be best served by combining enzymes in 
vitro, this in turn may require further engineering The identification of new 
gene clusters will provide opportunities to add new enzyme activities to such 
an in vitro tool kit. 
It remains an open question whether enzymes in the patellamide pathway (for 
example) form protein-protein interactions (PPIs) which could allow 
intermediates and substrates to be more efficiently or rapidly “funneled” 
through the pathway. Domains of unknown function (DUF) could acts as 
scaffolds facilitating these PPis. A key challenge is to combine the simple 
substrate specificity of PatGMac with the turnover rates of other 
macrocyclases; this will be achieved either by making PatGmac faster or the 
redesigning the recognition elements of the faster enzymes. In either 
approach detailed structural and mechanistic information will be essential. 
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Figure legends 
 
Figure 1  
Exploring and improving the biosynthesis of cyanobactins. 
(a) Natural products are synthesized as a precursor peptide (“E” on figure 1A), 
which is sequentially processed by the action of cyclodehydratase proteins 
responsible for heterocycle formation (“D” on figure 1A), a serine protease 
(“A” on figure 1A), a macrocyclase (“G” on figure 1A), and finally modified by 
prenylation (“F” on figure 1A) and/or oxidation (oxidase domain of the “G” 
protein on figure 1A). 
(b) There is considerable potential for engineering cyanobactins. 
 
Figure 2 
Structure based design of a constitutively active cyanobactin 
heterocyclase.  
(a) The structure of LynD (4v1v) in complex with its substrate peptide PatE’. 
The two monomers are shown in orange and teal (chain A) and green (chain 
B), and the peptide is shown in blue. The boxed region is further illustrated in 
the rest of the figure 2B-E. (b) Activation of the enzyme by peptide binding. 
LynD is aligned with TruD (4bs9, black) which was crystallized as an 
apoenzyme. Residues 371-415 on LynD form an alpha helix that interacts 
with the peptide, whereas the corresponding residues on TruD are disordered.  
(c) The RiPP precursor peptide recognition element (RRE) proposed by 
Burkhart et al. [36**] comprising of three helices and three beta sheets, in the 
N-terminal domain of LynD (teal). Residues in the RRE interacts with residues 
on PatE’ and mediates its binding. (d) Model of substrate binding. PatE’ (blue) 
was partially ordered in the structure. It is postulated that from the interface 
between the N-terminal domain of chain A (teal) and the C-terminal domain of 
chain B (green), PatE’ extends to the nucleotide-biding active site of chain B, 
where the core peptide region (cyan) is catalysed. (e) Model of the fusion 
enzyme. Part of the leader peptide from PatE’ was fused to the N-terminus of 
LynD via a linker region (purple). The fused enzyme is thought to be 
constitutively active and able to bind and process leaderless peptides (cyan).  
(f) The kinase model of heterocyclization. For simplicity the substrate was 
shown as a pentapeptide with the sequence TFCAYD, the F and C 
highlighted in green. 
 
Figure 3 
Making and breaking peptide bonds 
(a) overlay of the crystal structures of PatA (PDB 4h6v) and PatGmac 
(macrocyclase domain, PDB 4akt), showing that the three-dimensional 
structure is largely conserved between these two proteins catalyzing opposite 
reactions. The pink box highlights a helix-loop-helix motif thought to be crucial 
for protecting the acyl-enzyme intermediate from a water nucleophile in the “G 
proteins”. The inset shows the active site of PatGmac, in which the site chain 
for the catalytic histidine was added (since the complex structure was 
determined with a histidine to alanine mutant) and the three initial residues 
form the core sequence, labeled P6, P7, and P8 were added according to a 
structure prediction carried out using PEPFOLD (http://bioserv.rpbs.univ-
paris-diderot.fr/services/PEP-FOLD/). (b) The mechanism proposed for the 
macrocyclase enzyme, differs from serine proteases in that the formation of 
the second tetrahedral intermediate, the N-terminal amine of the peptide acts 
as a nucleophile not water.  
 
Figure 4  
Oxidation and prenylation 
(a) Simplified reaction scheme for the reaction catalyzed by the thiazoline 
and/or oxazoline oxidase protein. During the course of the reactions, oxidized 
flavine mononucleotide (FMN-ox) receives either one hydride and one proton 
or 2 single electrons and 2 protons from the thiazoline or oxazoline, 
generating reduced flavine mononucleotide (FMN-red). The exact mechanism 
remains to be determined. The catalytic competent FMN-ox is produced by 
reaction with oxygen to release hydrogen peroxide. (b) Tyrosine O- and C-
prenylation as examples of prenylation in cyanobactins. The hydroxyl group 
on tyrosine is reverse O-prenylated by LynF using DMAPP (Dimethylallyl 
pyrophosphate). The product can subsequently undergo non-enzymatic 
Claisen rearrangement to give C-prenylated tyrosine. 
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